$RLFTF dd by clambottler (copy) - SUMMARY HOUSTON
Post# of 653
(Total Views: 396)
Posted On: 12/02/2020 10:49:35 AM
$RLFTF dd by clambottler (copy) - SUMMARY HOUSTON: - AVIPTADIL EIND - 45 PATIENTS
All patients with comparable comorbidity from the same ICU, treated by the same clinical team, in the same time-frame who received maximal standard of care (SOC).
21 consecutively admitted patients with Critical COVID-19, treated with intravenous aviptadil (synthetic VIP), AND with maximal standard of care (SOC)
24 admitted patients with Critical COVID-19, treated with maximal standard of care (SOC)
Did not receive intravenous aviptadil.
HOUSTON EIND RESULTS AT 28 DAYS
Results: Nineteen of 21 patients survived to day 28 in the aviptadil-treated group compared to 4 of 24 control patients (90% vs 17%; P<.0001).
Kaplan-Meier analysis demonstrates a 9-fold advantage in probability of survival (Hazard Ratio 0.113; 95% CL 0.037, 0.343).
A similar 9-fold advantage was seen in cumulative probability of Recovery from Respiratory Failure (Hazard ratio: 0.115; 95% CL: 0.0254, 0.5219).
A mean 6.1 point difference in the 10 point WHO Ordinal Scale for COVID-19 was seen between aviptadil-treated patients, who exhibited a 2.6 point mean improvement from time of ICU admission vs. those treated with standard of care who exhibited a mean 3.5 point mean decrement (Wilcoxon rank sum: P<.001).
Improved radiographic appearance was seen in both lungs of 17 patients and in one lung of 2 treated patients.
Four of 5 aviptadil-treated patients initially on Extracorporeal Membrane Oxygenation (ECMO) have been decannulated, compared to 3 of 13 ECMO-treated controls (80% vs. 23%;P=.045). A 75% (95% CI±3%: P<.001) reduction in IL-6 was seen.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228
HOUSTON EIND RESULTS AT DAY 60
Overall, 81% of RLF-100™-treated patients survived beyond 60 days, compared to 17% of control patients. Patients treated with RLF-100™ demonstrated a 9-fold increased probability of survival and recovery from respiratory failure, with a high degree of statistical significance. Statistical analysis was performed by Prof. Phil Lavin, FASA, FRAPS of the Boston Biostatistical Research Foundation.
https://www.prnewswire.com/news-releases/neur...50707.html
All patients with comparable comorbidity from the same ICU, treated by the same clinical team, in the same time-frame who received maximal standard of care (SOC).
21 consecutively admitted patients with Critical COVID-19, treated with intravenous aviptadil (synthetic VIP), AND with maximal standard of care (SOC)
24 admitted patients with Critical COVID-19, treated with maximal standard of care (SOC)
Did not receive intravenous aviptadil.
HOUSTON EIND RESULTS AT 28 DAYS
Results: Nineteen of 21 patients survived to day 28 in the aviptadil-treated group compared to 4 of 24 control patients (90% vs 17%; P<.0001).
Kaplan-Meier analysis demonstrates a 9-fold advantage in probability of survival (Hazard Ratio 0.113; 95% CL 0.037, 0.343).
A similar 9-fold advantage was seen in cumulative probability of Recovery from Respiratory Failure (Hazard ratio: 0.115; 95% CL: 0.0254, 0.5219).
A mean 6.1 point difference in the 10 point WHO Ordinal Scale for COVID-19 was seen between aviptadil-treated patients, who exhibited a 2.6 point mean improvement from time of ICU admission vs. those treated with standard of care who exhibited a mean 3.5 point mean decrement (Wilcoxon rank sum: P<.001).
Improved radiographic appearance was seen in both lungs of 17 patients and in one lung of 2 treated patients.
Four of 5 aviptadil-treated patients initially on Extracorporeal Membrane Oxygenation (ECMO) have been decannulated, compared to 3 of 13 ECMO-treated controls (80% vs. 23%;P=.045). A 75% (95% CI±3%: P<.001) reduction in IL-6 was seen.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228
HOUSTON EIND RESULTS AT DAY 60
Overall, 81% of RLF-100™-treated patients survived beyond 60 days, compared to 17% of control patients. Patients treated with RLF-100™ demonstrated a 9-fold increased probability of survival and recovery from respiratory failure, with a high degree of statistical significance. Statistical analysis was performed by Prof. Phil Lavin, FASA, FRAPS of the Boston Biostatistical Research Foundation.
https://www.prnewswire.com/news-releases/neur...50707.html
(0)
(0)Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ